Naftzger J. Christopher 4
4 · Arbutus Biopharma Corp · Filed Jul 12, 2023
Insider Transaction Report
Form 4
Naftzger J. Christopher
General Counsel and CCO
Transactions
- Award
Stock Option (Right to Buy)
2023-07-10+500,000→ 500,000 totalExercise: $2.26Exp: 2033-07-10→ Common Shares (500,000 underlying)
Footnotes (2)
- [F1]Reflects the closing price of the Issuer's common shares on the Nasdaq Stock Market on July 10, 2023, the date of the grant.
- [F2]This option shall vest over a four-year period, with 25% of the shares subject to the option vesting on the first anniversary of the grant date and the remaining 75% of the shares subject to the option vesting over the subsequent three-year period in substantially equal monthly installments at a rate of 1/48th of the total shares subject to the option each month, subject to the Reporting Person's continuous service as of each vesting date.